

Monday 27 January 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Wednesday 22 January 2025. I am pleased to confirm the following.

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Pharmacy don't hold this information

Q1a. Of these patients, how many commenced treatments at your trust within the last 6 months?

30

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 6

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) 6

Pola-BR (polatuzumab vedotin with rituximab and bendamustine) 1

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) 4

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) 0

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) 0

R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) 3
(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) 2

R-GemOX (rituximab, gemcitabine and oxaliplatin) 1

Axicabtagene ciloleucel 0

Tisagenlecleucel 0

Epcoritamab 3

Loncastuximab tesirine 0

Glofitamab 1

Any other SACT 1

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Pharmacy don't hold this information

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Pharmacy do not hold this information

Axicabtagene ciloleucel (Yescarta)

Tisagenlecleucel**Pola-BR (polatuzumab vedotin with rituximab and bendamustine)****R-GemOX (rituximab, gemcitabine and oxaliplatin)****Stem cell transplant or bone marrow transplant (autologous or allogeneic)****Any other treatments****Q4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?**

Pharmacy do not hold this information

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

Pharmacy do not hold this information

CAR-T Therapy (E.g. Axicabtagene ciloleucel)

Pharmacy do not hold this information

Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Pharmacy do not hold this information

Any other treatment

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead

For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.